Beun G D
Eli Lilly Nederland, Medische Afdeling, Leiden.
Ned Tijdschr Geneeskd. 1998 Feb 21;142(8):392-6.
In a limited number of cases, T cell based cancer immunotherapy has proven its clinical efficacy. Indications are restricted to certain haematological malignancies, relapsed after allogeneic bone marrow transplantation, and tumours against which an autologous T cell response can be elicited or boosted, such as melanomas and renal carcinomas. T cell based immunotherapy of non-immunogenic tumors is possible using bispecific antibodies.
在少数情况下，基于T细胞的癌症免疫疗法已证明其临床疗效。其适应症仅限于某些血液系统恶性肿瘤、异基因骨髓移植后复发的肿瘤，以及能够引发或增强自体T细胞反应的肿瘤，如黑色素瘤和肾癌。使用双特异性抗体对非免疫原性肿瘤进行基于T细胞的免疫治疗是可行的。
